AZ-TITAN

A Phase 1, open-label study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD5492 following administration of a single ascending dose and dose-escalation in adult participants

Condition studied : Systemic lupus erythematosus, Idiopathic inflammatory myopathies
Treatment : Repeated injections of AZD5492
Sponsor : Astrazeneca
Principal Investigator : Pr. Christian Jorgensen
: EU CT 2024-511346-39-00
Investigator
Pr. Christian Jorgensen
Director
Rechercher sur le site